PILA PHARMA AB (publ) (PILA) Starts Enrollment for 8-Patient Safety Cohort in 12-Week Obesity Trial

PILA PHARMA AB (publ) initiated and activated its first site and began enrollment for Part 1 (8 participants) of PP-CT04, a 12—week, randomized, placebo—controlled trial of XEN—D0501 in obesity. Part 2 may start after ≥5 weeks dosing in Part 1 and a favorable safety review.Material DetailsContext b…